Today, the shares of mondoBIOTECH holding Ltd. have been listed in accordance with the main standard and are traded at SIX Swiss Exchange for the first time. The opening price on SIX Swiss Exchange was CHF 290.00. This corresponds to a market capitalisation of CHF 362.1 millions mondoBIOTECH holding Ltd. belongs not only to the SPI®, but also to the SPI EXTRA®.
According to the listing prospectus, 1’248’671 registered shares to a nominal price of CHF 0.10 were entered in the Commercial Register.
mondoBIOTECH is focused on the continuous discovery of medicinal product candidates, by redirecting already known peptides and other immunomodulating substances for the use of treatment of rare and neglected diseases, with the aim of licensing-out or selling them to third parties. Thus far more than 300 such candidates have been discovered; seven have already been licensed to pharmaceutical and biotechnology companies. More than just a company, mondoBIOTECH holding Ltd. is a community of people dedicated to the search for treatments of rare and neglected diseases and to the support of sufferers from these diseases. The community in question is made up of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills. mondoBIOTECH was founded in 2001 as a small privately held concern and is now being listed on the Swiss Stock Exchange under the SIX Swiss Exchange Ticker Symbol RARE. The ticker symbol RARE stands for mondoBIOTECH Holding Ltd.’s core ambition: to improve the lives of patients afflicted by rare and neglected diseases. mondoBIOTECH believes that people affected by, or involved in rare diseases will benefit thanks to the public listing of mondoBIOTECH holding Ltd.
In December 2008, mondoBIOTECH holding Ltd had 19 equivalent employees. According to the annual report of 31 December 2008, the company generated a turnover of CHF 14.5 millions.
